본문바로가기

Antimicrobial/Antiviral agents

메인페이지로 이동
Business
Life Science
ETC
혈액순환개선제
Ozex Tab.
Category
ETC
Indication(s)·Usage
    • Effective strains
      Staphylococcus, Streptococcus, Streptococcus pneumoniae, Enterococcus, Escherichia coli, Klebsiella, Hemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, Citrobacter, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, Acinetobacter, Salmonella (except Salmonella typhi, Paratyphoid bacillus), Shigella, Peptostreptococcus anaerobius, Propionibacterium acnes, Bacteroidosis
    • Indication(s)
      • - Community acquired infection pneumonia, diffuse panbronchiolitis, chronic bronchitis, bronchiectasis (in case of infection), secondary infection of chronic respiratory diseases
      • - Otitis media (except preoperative use against bone-metastasized chronic otitis media and chronic cholesteatomatous otitis media), sinusitis, suppurative sialoadenitis
      • - Periodontitis, pericoronitis, maxillary inflammation
      • - Pyelonephritis, cystitis, prostatitis, epididymitis, gonococcal urethritis
      • - bacillary dysentery, infectious enteritis
      • - cholecystitis, cholangitis
      • - mastitis, superficial secondary infection of traumaㆍsurgical wound, pouchitis (including pustular acne), furuncle, carbuncle, erysipelas, cellulitis, lymphangitis (lymphadenitis), whitlow, pyogenic paronychia, subcutaneous abscess, hidradenitis, acne conglobata, infective atheroma, perianal abscess
      • - Uterine adnexitis, intrauterine infection, bartholinitis
      • - Blepharitis, hordeolum, dacryocystitis, anophthalmia
    • As is with this drug, Fluoroquinolones may cause serious adverse effects. Administration of this drug should be to patients who are undergoing no other methods of treatment for acute bacterial sinusitis, chronic bronchitis, acute bacterial aggravation of chronic obstructive pulmonary disease, simple urinary tract infection, or acute otitis media
Effective components
Tosufloxacin Tosylate Hydrate
150.0 mg

Active ingredient(s) and Contents

  • Effective components

    • Tosufloxacin Tosylate Hydrate
      150.0 mg

  • Other

    • Talc, L-Aspartic Acid, Corn starch, Polyethylene Glycol(105) · Polyoxypropylene Glycol(5) Copolymer, Magnesium Stearate, Hydrated Silicon Dioxide, Hydroxypropyl cellulose, Titanium Oxide, Microcrystalline Cellulose, Purified Water, Carnauba Wax, Hypromellose

Dosage and administration

  • Orally administer 300 to 450 mg of tosulfloxacin tosylate in 2 to 3 divided doses daily in adults. If it is considered severe or ineffective, the dose can be administered up to 600 mg daily.

    The dose may be adjusted depending on the patient’s age and symptoms.

Storage and handling

  • Well-closed container, keep at room temperature (1~30°C)